Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Oncology and Therapy · 2025-12 · 13 (4) · 1055-1070
DOI: 10.1007/s40487-025-00380-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology and Therapy, online erschienen am 13.09.2025. Verfasst von Talha Munir und 12 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Teaching Hospitals NHS Trust, Leeds, UK. tmunir@nhs.net. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nucleus Group.
Abstract (Originalsprache)
INTRODUCTION: Compared with chemoimmunotherapy, both zanubrutinib monotherapy and venetoclax plus obinutuzumab prolong progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL). Matching-adjusted indirect comparison (MAIC) can be used to compare the efficacy and safety of different treatment regimens when no head-to-head trial has compared the treatments. METHODS: Patient matching was conducted using unanchored MAIC propensity-score weighting to compare PFS, overall survival (OS), tolerability, and adverse events (AEs) of interest (AEIs; grade 3-4 infections, neutropenia, febrile neutropenia, and/or thrombocytopenia and AEs leading to treatment discontinuation) on the basis of data from patients in SEQUOIA for zanubrutinib and aggregate data from CLL14 for venetoclax plus obinutuzumab. Because SEQUOIA occurred during the pandemic, analyses were also conducted to adjust for coronavirus disease 2019 (COVID-19) infections. RESULTS: After matching and adjustment, baseline characteristics of the zanubrutinib group in SEQUOIA were well balanced with the CLL14 population (N = 216), with an effective sample size of 163 for the zanubrutinib group. After matching for baseline characteristics, zanubrutinib demonstrated a robust PFS benefit compared with venetoclax plus obinutuzumab (hazard ratio, 0.66 [95% confidence interval, 0.44-0.97]; P = 0.0351) and higher PFS probability at landmark points (60-month landmarks of 73.9% versus 63%, respectively). OS trended in favor of zanubrutinib. Overall, AEs of any grade over time were comparable in the zanubrutinib safety and venetoclax plus obinutuzumab populations. Zanubrutinib was associated with lower rates of selected AEIs compared with venetoclax plus obinutuzumab at all time points, except for grade 3-4 infections after 156 weeks. After adjusting for COVID-19, zanubrutinib was associated with a significantly lower incidence of grade 3-4 infections at 104 weeks but similar incidences of grade 3-4 infections versus venetoclax plus obinutuzumab during the overall follow-up period. CONCLUSIONS: Continuous treatment with zanubrutinib in treatment-naïve patients with CLL/small lymphocytic lymphoma resulted in prolonged PFS and a favorable safety profile compared with fixed-duration venetoclax plus obinutuzumab. TRIAL REGISTRATION NO: SEQUOIA (NCT03336333); CLL14 (NCT02242942).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Leeds Teaching Hospitals NHS Trust, Leeds, UK. tmunir@nhs.net.
- St James's Hospital, Beckett St, Harehills, Leeds, LS9 7TF, UK. tmunir@nhs.net.
- Nottingham University Hospital, Nottingham, UK.
- BeOne Medicines Ltd., Shanghai, China.
- BeOne Medicines Ltd., San Carlos, CA, USA.
- BeOne Medicines Ltd., Schiphol, The Netherlands.
Förderung
- Nucleus Group
Zitieren
APA
Munir, T., Martinez-Calle, N., Xu, S., Yang, K., Ge, X., Ali, A. K., Mohseninejad, L., Dobi, B., Rakonczai, P., Ma, H., Williams, R., Aldairy, W., & Lamanna, N. (2025). Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Oncology and Therapy, 13(4), 1055-1070. https://doi.org/10.1007/s40487-025-00380-0
Vancouver
Munir T, Martinez-Calle N, Xu S, Yang K, Ge X, Ali AK, et al. Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Oncology and Therapy. 2025;13(4):1055-1070. doi:10.1007/s40487-025-00380-0
BibTeX
@article{Munir2025,
author = {Munir, Talha and Martinez-Calle, Nicolás and Xu, Sheng and Yang, Keri and Ge, Xiaoyun and Ali, Ayad K and Mohseninejad, Leyla and Dobi, Balázs and Rakonczai, Pal and Ma, Han and Williams, Rhys and Aldairy, Wassim and Lamanna, Nicole},
title = {Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma},
journal = {Oncology and Therapy},
year = {2025},
volume = {13},
number = {4},
pages = {1055--1070},
doi = {10.1007/s40487-025-00380-0}
}
EUVIMED